http://researchspace.auckland.ac.nz

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage. http://researchspace.auckland.ac.nz/feedback

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.
THE EFFECTIVENESS OF MEDICINES
The Relationship between Patient and Prescriber Expectations of Effectiveness of Medicines and Compliance

Gail Jocelyn Ware

A thesis submitted for the Degree of Doctor of Philosophy, Faculty of Medicine and Health Sciences, University of Auckland, 1997.
ABSTRACT

Effectiveness of medicines as reported in the literature can be difficult to interpret and explain to patients in clinical practice. A patient-orientated measure of effectiveness, the Category of Effectiveness (COE) was developed in 1988 by Dr Holford, Department of Pharmacology and Clinical Pharmacology, University of Auckland, School of Medicine. This was designed to examine the effectiveness of medicines in terms of easily understood patient-orientated outcomes which may influence the patient's daily living or quality of life.

As part of their pharmacology training, third-year medical students were assigned two medicines to evaluate in terms of COE and asked to calculate a rate/1000 treatments or rate/1000 treatment years i.e. a Rate of Effectiveness (ROE). Interviews with three health professionals to obtain their opinions of the assigned medicines in terms of COE and ROE were recorded. An ordered scale of effectiveness, the Likelihood of Effectiveness (LOE), was developed by Dr Holford and the author in order to review these student projects. A review by the author of 201 of these projects over a five year period, suggests that health professionals expectations of some commonly prescribed medicines are over-optimistic.

A literature search to obtain effectiveness information in terms of COE and LOE of twelve commonly prescribed medicines, Augmentin, cefaclor, beclomethasone, salbutamol, atenolol, captopril, enalapril, ranitidine, paracetamol, diclofenac, aspirin, and triazolam was undertaken. Such information was found to be limited in the literature as clinical trial results are seldom expressed in such terms.

Opinions of patients and prescribers about The Category of Effectiveness (COE) and Likelihood of Effectiveness (LOE) of commonly prescribed medicines have not been examined in clinical practice. The influence these may have on medicine use was therefore surveyed for the twelve medicines listed above. One hundred and fifty-three patients received 247 prescriptions for one or more of these medicines. Expectations of patient and corresponding prescriber were similar in terms of COE, but LOEs differed significantly for 8 of the 12 medicines. Neither COE nor LOE were significantly related to patient compliance which was measured after 5-10 days. Most compliance-failure was seen in patients whose medicine was newly prescribed for short-term treatment. Information other than basic instructions was received by <25% of patients from either the prescriber or the pharmacist. At the surgery/hospital only 19% of patients remembered receiving written
information about their medicine, which increased to 22% at the home visit. Of the patients who completed the medicines information questionnaire, only 59/152 (38.6%) would like more general information about their medicines. Despite this, 139/152 (91.4%) patients would like more specific information on how their medicine works, and 130/152 (85.5%) want to know how well it can be expected to work. This information has not been given to patients in the past.

It was hypothesised that providing effectiveness information to patients may have some effect on compliance. The influence on compliance that providing written medicine effectiveness information as pamphlets from community pharmacists may have, was examined for 211 patients in a double-blind controlled trial. Patients who presented a prescription for beclomethasone for asthma or enalapril for hypertension were invited to participate. Each patient received one of three pamphlets, 1. specific medicine information pamphlet, 2. specific medicine information plus effectiveness information, 3. a control pamphlet containing general medicine information. Medicine knowledge was significantly increased by both the medicine information pamphlet \( p=0.028 \) and the medicine and effectiveness information pamphlet \( p=0.016 \) compared to control. Significantly more beclomethasone than enalapril patients showed compliance-failure \( p=0.001 \) although this was independent of the pamphlet given. Expectations of LOE were related to patient compliance for beclomethasone patients, but not for enalapril patients. Significantly more beclomethasone patients with higher expectations of LOE were compliant \( p=0.017 \). Satisfaction with the information contained in the pamphlet had a positive effect on patient compliance with beclomethasone individually. Patient-orientated measures of effectiveness such as COE (Category of effectiveness) and LOE (Likelihood of effectiveness) can identify patient expectations, increase patient knowledge and may provide some insight into patient compliance failure.
PRESENTATIONS AND PUBLICATIONS ARISING FROM THIS THESIS

Paper presented at ASCEPT Conference, Brisbane 1993
Ware GJ, Holford NHG. Effectiveness of medicines - the influence of patient and prescriber expectations of effectiveness
Published in Proceedings of ASCEPT 1993

Paper presented at the ASCEPT (New Zealand) Conference Wellington 1995
Ware GJ, Holford NHG. Knowledge of the effectiveness of medicines - does it alter patient compliance?

Poster presented at the ASCEPT Conference, Adelaide 1995
Ware GJ, Holford, NHG. Knowledge of the Effectiveness of Medicines - Does it alter compliance with long-term medicines?
Abstract Published in Proceedings ASCEPT 1995 p158

Paper presented at the APSA Conference Adelaide 1995
Abstract Published

Ware G. J., Holford, NHG. Patients' perceptions of the effectiveness of their medicines - Does this alter long-term compliance? (Abstract) Aust J Hosp Pharm 1996;26:4:506

Paper presented at the PSA Congress Melbourne 1996
Abstract Published

ACKNOWLEDGEMENTS

This thesis was made possible by the advice and encouragement of my supervisors Dr. Nick Holford and Dr. Robin Briant. They have given freely of their time and advice which has been greatly appreciated. I would particularly like to thank Dr. Holford for his continued support and speedy replies via e-mail, which has enabled me to be with my husband in Melbourne whilst writing up this research. My thanks also to Dr. Bruce Arroll who has provided valuable advice for the general practice project and given his time reviewing CHAPTER 4. The Department of General Practice has also provided comments and advice for the general practice project.

Particular thanks also to Gregory Gamble, Biostatistitian, from the Clinical Trials Unit who has given assistance both personally and via e-mail in working with SAS.

This work would not have been possible without the help and assistance of the general practitioners who allowed me to conduct the survey in their practices and the staff at the medical wards at Auckland hospital and I am most grateful to them. My colleagues in community pharmacy have also provided unceasing support and particular thanks to those who participated in the pamphlet project.

I would like also to acknowledge the financial assistance of the Pharmacy Education and Research Foundation for the pamphlet project and also Glaxo N.Z. Pty Ltd. who funded the electronic scales used in this project.

The staff and members of the Department of Pharmacology and Clinical Pharmacology have provided continued help and encouragement for this work. In addition I would also like to acknowledge the help of the Department of Pharmacology, and the Department of Pharmacy Practice at Monash University, Melbourne who have assisted with e-mail and library access respectively during the writing of this thesis.

I would also like to thank my family on both sides of the Tasman who have helped me over the past four years, particularly my husband Neil without whose unfailing patience and support this thesis could not have been completed. After a business transfer to Melbourne, he was happy for me to complete this research in Auckland, before joining him there. This thesis would not have been possible without such encouragement.
TABLE OF CONTENTS

ABSTRACT ................................................................................................................................. ii
PRESENTATIONS AND PUBLICATIONS ................................................................................ iv
ACKNOWLEDGEMENTS ........................................................................................................ v
TABLE OF CONTENTS ........................................................................................................ vi
LIST OF TABLES .................................................................................................................... xiv
LIST OF FIGURES ................................................................................................................ xvii
LIST OF APPENDICES .......................................................................................................... xviii
LIST OF ABBREVIATIONS ................................................................................................... xix

SECTION 1 - INTRODUCTION

CHAPTER 1 - MEDICINES - Effectiveness, Information and Patient Compliance 20

PART A - MEDICINE EFFECTIVENESS

1.1 Medicine and Health. ........................................................................................................ 21

1.1.1 The effectiveness of medicines .................................................................................... 22

1.1.1.1 Efficacy ................................................................................................................ 23
1.1.1.2 Effectiveness ........................................................................................................ 23
1.1.1.3 Appropriate use by the prescriber ..................................................................... 24
1.1.1.4 Compliance ......................................................................................................... 25

1.1.2 Measures of effectiveness .......................................................................................... 25
1.1.3 Are these measures adequate? ................................................................................ 25
1.1.4 What is important to the patient? ............................................................................ 26
1.1.5 How can we express medicine effectiveness in more meaningful terms? ............ 26

PART B - MEDICINE INFORMATION

1.2 Introduction ...................................................................................................................... 29

1.2.1 For the Prescriber ..................................................................................................... 29

1.2.1.1 Sources of information ...................................................................................... 29
1.2.1.2 Information available for new medicines. ....................................................... 32
1.2.1.3 Dissemination of the results of clinical trials. .................................................. 32
1.2.1.4 Limitations ....................................................................................................... 33
1.2.1.5 Academic detailing ............................................................................................ 35
SECTION 2 - STANDARDS OF EFFECTIVENESS

CHAPTER 3 - EFFECTIVENESS OF TWELVE COMMONLY PRESCRIBED MEDICINES

3.1 Introduction ................................................................................. 81

3.2 Methods ..................................................................................... 82
  3.2.1 Measures of effectiveness .................................................. 82
    3.2.1.1 Category of effectiveness (COE) .................................. 82
    3.2.1.2 Likelihood of effectiveness (LOE) ................................. 83

3.2.2 Medicines evaluated ................................................................. 84

3.2.3 Literature Review ................................................................. 85

3.3 Results ....................................................................................... 85
  3.3.1 Augmentin ............................................................................ 85
    3.3.1.1 Upper respiratory tract infections ............................... 86
    3.3.1.2 Lower respiratory tract infections ............................... 86
    3.3.1.3 Acute otitis media ....................................................... 87
    3.3.1.4 Urinary tract infections .............................................. 88

3.3.2 Cefaclor ................................................................................. 90
    3.3.2.1 Otitis media ............................................................... 90
    3.3.2.2 Lower respiratory tract infections - bronchitis and pneumonia .................................................. 90
3.3.3 Beclomethasone ................................................. 92
  3.3.3.1 Asthma ................................................. 92
  3.3.3.2 Allergic rhinitis (Hay Fever) ....................... 95
3.3.4 Salbutamol .................................................. 96
  3.3.4.1 Asthma ................................................. 98
3.3.5 Atenolol ..................................................... 99
  3.3.5.1 Post Myocardial infarction .......................... 99
  3.3.5.2 Angina ................................................. 100
3.3.6 Captopril ................................................... 102
  3.3.6.1 Congestive Heart failure .......................... 103
  3.3.6.2 Hypertension ......................................... 105
3.3.7 Enalapril .................................................... 106
  3.3.7.1 Congestive heart failure (CHF) ..................... 106
  3.3.7.2 Hypertension ......................................... 107
3.3.8 Ranitidine .................................................. 109
  3.3.8.1 Ulcer treatment ...................................... 109
  3.3.8.2 Prevention of Ulcer Recurrence ................... 111
3.3.9 Paracetamol ................................................ 111
  3.3.9.1 COE6 (fewer painful days) - LOE .................. 112
3.3.10 Diclofenac ................................................ 115
  3.3.10.1 Rheumatoid arthritis .............................. 115
  3.3.10.3 Pain relief .......................................... 117
  3.3.10.4 Trauma .............................................. 118
3.3.11 Aspirin ................................................... 119
  3.3.11.1 Antiplatelet activity .............................. 120
3.3.12 Triazolam ................................................ 125
3.4 Discussion .................................................... 128
3.5 Conclusion ................................................... 129

SECTION 3 - RESEARCH PROJECTS

CHAPTER 4 - THE INFLUENCE ON MEDICINE USE OF PRESCRIBER AND
PATIENT EXPECTATIONS OF MEDICINES ......................... 130
4.1 Introduction .................................................. 130
4.2 Expectations of Medicine Effectiveness .................... 131
4.2.1 The patient ................................................................. 131
4.2.2 The prescriber ............................................................ 131
4.2.3 Compliance with prescribed medicine treatment ............... 132
4.2.4 Patient medicine information ...................................... 132

4.3 Aims ........................................................................ 133

4.4 Methods ..................................................................... 134

4.4.1 Commonly prescribed medicines ................................. 134
4.4.2 Measures of medicine effectiveness ............................ 134
4.4.3 Project setting .......................................................... 134
  4.4.3.1 General practice setting ....................................... 134
  4.4.3.2 Hospital Setting .................................................. 135

4.4.4 Recruitment of patients .............................................. 135
  4.4.4.1 Patients from general practice .............................. 135
  4.4.4.2 Recruitment of hospital patients ........................... 137

4.4.5 Measures .................................................................. 137
  4.4.5.1 Potential predictor variables ................................. 137
  4.4.5.2 Patient Decisions to Take The Prescribed Medicines .... 138
  4.4.5.3 Patient Medicine Information Needs ...................... 138
  4.4.5.4 Patient numbers .................................................. 139

4.4.6 Analysis. .................................................................. 139
  4.4.6.1 Methods .............................................................. 139
  4.4.6.2 Possible Sources of Bias ...................................... 140

4.4.7 Pilot study evaluation ................................................. 141

4.5 Results - Part A and B Medicine Effectiveness and Compliance. 141

4.5.1 General practitioners .................................................. 141

4.5.2 Patient population ...................................................... 142
  4.5.2.1 Ethnicity ............................................................. 142
  4.5.2.2 Age and gender distribution ................................ 142
  4.5.2.3 Home visits ....................................................... 144

4.5.3 Medicines .................................................................. 144
  4.5.3.1 Severity of illness ................................................. 146

4.5.4 Opinions on measures of effectiveness .......................... 147
  4.5.4.1 Category of effectiveness ..................................... 147
  4.5.4.2 Likelihood of effectiveness (LOE) ......................... 149

4.5.5 Medicine information knowledge .................................. 149
4.5.6 Compliance ................................................................. 151

4.6 Results - Part C. Medicine Information Questionnaire ....................................................... 158

4.6.1 Patient perceptions of medicine information needs .......................................................... 158

4.6.1.1 Question A: Current sources of medicine information .................................................. 158
4.6.1.2 Question B: More information ...................................................................................... 160
4.6.1.3 Question C: Who to talk to about medicines .................................................................. 160
4.6.1.4 Question D: Preference for form of medicine information or extra information .................. 162
4.6.1.5 Question E: Effectiveness information .......................................................................... 162
4.6.1.6 Question F: Provision of medicine information service ............................................... 164
4.6.1.7 Question G: The importance of such a service to patients .......................................... 165
4.6.1.8 Question H: Frequency of collecting the medicine prescribed ..................................... 165
4.6.1.9 Question K: Cost of the prescription to the patient ......................................................... 165
4.6.1.10 Question L: Perceived frequency of taking medicines as directed .................................. 166

4.7 Discussion ........................................................................ 167

4.7.1 Category of effectiveness (COE) ...................................................................................... 167
4.7.2 Likelihood of effectiveness ................................................................................................. 168
4.7.3 Compliance ......................................................................................................................... 172
4.7.4 Medicine information perceptions .................................................................................... 173
4.7.5 Limitations .......................................................................................................................... 177

4.8 Conclusions ........................................................................ 177

4.8.1 Part A and B: Medicine effectiveness and compliance ...................................................... 177
4.8.2 Part C ..................................................................................................................................... 178

4.9 Implications of this Project .................................................................................................... 178

CHAPTER 5 - DOES INFORMATION ON EFFECTIVENESS ALTER COMPLIANCE WITH LONG-TERM MEDICINES? .............................................................. 180

5.1 Introduction ......................................................................... 180
5.2 Aims ...................................................................................... 180
5.3 Methods .................................................................................. 180

5.3.1 Project type ............................................................................... 180
5.3.2 Pamphlets ................................................................................ 181
5.3.2 Development of pamphlets

5.3.2.1 Testing of pamphlets

5.3.2.3 Specific Medicine Information

5.3.2.4 Medicine and Effectiveness information (COE and LOE)

5.3.2.5 General Medicine Information

5.3.3 Compliance

5.3.3.1 Compliance Measures

5.3.3.2 Measurement of doses taken

5.3.4 Expectations of effectiveness

5.3.5 Medicine knowledge

5.3.6 Demographics

5.3.6.1 Location of Project

5.3.6.2 Invitation of Pharmacies

5.3.6.3 Recruitment of patients

5.3.6.4 Protocol for pharmacists

5.3.6.5 Socioeconomic status

5.3.6.6 Follow-up home visits

5.3.7 Ethics approval and patient confidentiality

5.3.8 Analysis

5.4 Results

5.4.1 Patient population

5.4.1.1 Patient Enrolment

5.4.1.2 Reasons for withdrawal

5.4.1.3 Geographic distribution and ethnicity

5.4.1.4 Socioeconomic status

5.4.2 Comparability of medicine use by patients

5.4.2.1 Gender

5.4.2.2 Age

5.4.2.3 Total number of medicines taken

5.4.2.4 Length of time taking medicines (years)

5.4.2.5 Home visits

5.4.3 Pamphlets

5.4.3.1 Allocation of pamphlets

5.4.3.2 Distribution of pamphlets between genders
LIST OF TABLES

CHAPTER 2
2-1 Medicine Reports Reviewed .......................................................... 60
2-2 Opinions of COE on Antibiotics ...................................................... 61
2-3 Derived LOE and Rates of Effectiveness of Antibiotics ..................... 62
2-4 Opinions on COE of Anti-asthmatics .............................................. 63
2-5 Derived LOE and Rate of Effectiveness of Anti-asthmatics ................ 64
2-6 Opinions on COE of Antihypertensives ......................................... 65
2-7 Derived LOE and Opinions on Rate of Effectiveness of Antihypertensives 66
2-8 Opinions on COE of Gastrointestinal Medicines ............................ 67
2-9 Derived LOE and Opinions on Rate of Effectiveness of Gastrointestinal Medicines ............................................................. 67
2-10 Derived LOE and Opinions on ROE of Paracetamol ......................... 68
2-11 Opinions on COE of NSAIDS ......................................................... 69
2-12 Derived LOE and Opinions on Rate of Effectiveness of NSAIDS ........ 69
2-13 Derived LOE and Opinions on ROE of Aspirin & Thrombolytics .......... 70
2-14 Derived LOE and Rate of Effectiveness of Triazolam ....................... 70
2-15 Summary of Health Professionals Opinions of LOE ......................... 79

CHAPTER 3
3-1 Medicines Evaluated ........................................................................ 84
3-2 Category and Likelihood of Effectiveness of Augmentin ..................... 89
3-3 Category and Likelihood of Effectiveness of Cefaclor ........................ 91
3-4 Category and Likelihood of Effectiveness of Beclomethasone ............... 94
3-5 Category and Likelihood of Effectiveness of Salbutamol ................... 97
3-6 Category and Likelihood of Effectiveness of Atenolol ....................... 101
3-7 Category and Likelihood of Effectiveness of Captopril ...................... 104
3-8 Category and Likelihood of Effectiveness of Enalapril ....................... 108
3-9 Category and Likelihood of Effectiveness of Ranitidine .................... 110
3-10 Category and Likelihood of Effectiveness of Paracetamol .................. 114
3-11 Category and Likelihood of Effectiveness of Diclofenac .................... 116
3-12 Category and Likelihood of Effectiveness of Aspirin as an Antiplatelet 122
3-13 Category and Likelihood of Effectiveness of Triazolam .................... 126
CHAPTER 4

4-1 Patient Information Needs .......................................................... 138
4-2 Location of General Practices ...................................................... 142
4-3 Age and Gender Distribution for Medicines .................................... 144
4-4 Frequency of Prescribing of Medicines ........................................ 146
4-5 Severity of Illness ........................................................................ 147
4-6 Frequency of Opinions on the Category of Effectiveness (COE) at Enrolment ................................................................. 148
4-7 Frequency of Opinions on the Likelihood of Effectiveness (LOE) at Enrolment ................................................................. 150
4-8 Knowledge of Specific Information about the Medicines at the Surgery/Hospital and the Home Visit ........................................... 151
4-9 Prescriptions Collected .................................................................. 153
4-10 Compliance in Relation to Setting ................................................ 153
4-11 Relationship of the Number of Medicines Taken to Compliance .... 154
4-12 Effect of Age-group on Compliance ............................................ 155
4-13 Relationship of Compliance to Information given at the Surgery/Hospital ................................................................. 155
4-14 Relationship of Compliance to Information Remembered at the Surgery/Hospital ................................................................. 156
4-15 Relationship of Compliance to the Information Remembered at the Home Visit ................................................................. 156
4-16 Relationship of Patient and Prescriber Expectations of LOE to Compliance ................................................................. 158
4-17 Patient Sources of Medicine Information ..................................... 158
4-18 Medicine Information Requirements ........................................... 160
4-19 Preferred Provider ....................................................................... 160
4-21 Ease of Talking to the Health Professional .................................... 162
4-21 Frequency of Health Professional Providing Medicine Information ................................................................. 162
4-22 Effectiveness Information .............................................................. 164
4-23 Type of Medicine Information Service Preferred .......................... 164
4-24 Importance of Provision of such a Medicine Information Service ................................................................. 165
4-25 Collection of Prescriptions ............................................................ 165
4-26 Cost to the Patient of Each Prescription Item ............................... 166
4-27 Expected Compliance ................................................................. 166
4-28 Suggested Aids for Compliance ................................................... 166
4-29 Comparison of Prescriber COE and Corresponding Patient LOE .... 171
CHAPTER 5

5-1 Patient Enrolment .................................................. 190
5-2 Reasons for Withdrawal .......................................... 190
5-3 Geographic Distribution and Ethnicity of Patients ....... 191
5-4 Number of Medicines Taken by Each Patient .......... 192
5-5 Length of Time Taking Beclomethasone/Enalapril .... 192
5-6 Number of Days Between Home Visits .................... 194
5-7 Distribution of Pamphlets ....................................... 194
5-8 Distribution of Pamphlets among Genders ............... 195
5-9 Distribution of Pamphlets amongst Age-groups ......... 195
5-10 The Number of Compliant Patients as Defined ...... 196
5-11 The Relationship of Patient Specific Variables to Compliance ............................................................................. 198
5-12 The Frequency of Compliance amongst Pamphlet Types ................................................................................. 198
5-13 The Relationship of Pamphlet Associated Variables to Compliance .................................................................... 199
5-14 Comparison of Patient Expectations of Compliance and Measured Compliance ......................................................... 200
5-15 Results of Morisky Scale Question Score ................. 201
5-16 Category of Effectiveness (COE) in relation to each pamphlet ............................................................................ 203
5-17 Likelihood of Effectiveness (LOE) in Relation to Each Pamphlet ........................................................................ 204
5-18 Effect of Each Pamphlet on Knowledge (Both Medicines) ............................................................................... 206
5-19 Effect of Each Pamphlet on Knowledge (Beclomethasone) ................................................................................ 207
5-20 Effect of Each Pamphlet on Knowledge (Enalapril) ......................................................................................... 207
5-21 Knowledge of Specific Information (Both Medicines) at the Pharmacy and Home Visit 1 .............................. 209
5-22 Kept Pamphlet for Future Reference .......................... 210
LIST OF FIGURES

CHAPTER 1
1-1 Patient Expectations of Effectiveness and Their Influence on Compliance
   [after The Health Belief Model of Godfrey et al. (Becker et al. 1979) ..... 28

CHAPTER 4
4-1 Location of General Practices .................................................. 136
4-2 Patient population ................................................................. 143
4-3 Comparison of Patient and Prescriber COE .................................. 145
4-4 Comparison of Patient and Prescriber LOE .................................. 145
4-5 Relationship of age to compliance .............................................. 152
4-6 Effect of COE on Compliance ................................................... 152
4-7 Effect of LOE on Compliance .................................................... 152
4-8 Patient Medicine Information Requirements ................................. 157
4-9 Preferred Format of Patient Medicine Information .......................... 157
4-10 Preferred Provider of Patient Medicine Information ...................... 159
4-11 Current Frequency of Patients Receiving Medicine Information from Health Professionals .......................... 159
4-12 Patients Requiring Effectiveness Information ............................... 161
4-13 Patients Preferred Medicine Information Service .......................... 163

CHAPTER 5
5-1 Location of Pharmacies ............................................................ 189
5-2 Patient Population ................................................................. 193
5-3 Compliance - Relationship to Pamphlet Type ................................. 197
5-4 Compliance - Patient Expectations vs Measured ............................. 197
5-5 Patients' Opinions of Category and Likelihood of Effectiveness ............ 202
5-6 Relationship of Age to Percent Doses Taken Correctly ....................... 205
5-7 Effect of Pamphlets on Medicine Knowledge .................................. 208
5-8 Patient Satisfaction with Each Pamphlet ....................................... 211

APPENDIX XIX
A-1a Relationship of Adherence Index to the Percentage of Compliant Patients 301a
A-1b Relationship of Adherence Scale to the Percentage of Compliant Patients 301a
<table>
<thead>
<tr>
<th>APPENDIX</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Student Project - Ethics Committee Assessment</td>
<td>261</td>
</tr>
<tr>
<td>II</td>
<td>Medicine &amp; Effectiveness Project. Ethical Approval</td>
<td>262</td>
</tr>
<tr>
<td>III</td>
<td>Patient Information Sheet</td>
<td>263</td>
</tr>
<tr>
<td>IV</td>
<td>Patient knowledge Assessment Sheet</td>
<td>265</td>
</tr>
<tr>
<td>V</td>
<td>Patient questionnaire - Investigator use</td>
<td>266</td>
</tr>
<tr>
<td>VI</td>
<td>Patient Medicines information Questionnaire</td>
<td>261</td>
</tr>
<tr>
<td>VII</td>
<td>Prescriber Information Sheet</td>
<td>272</td>
</tr>
<tr>
<td>VIII</td>
<td>Prescriber Questionnaire</td>
<td>274</td>
</tr>
<tr>
<td>IX</td>
<td>Does Information on Effectiveness alter Compliance - Ethics Approval</td>
<td>276</td>
</tr>
<tr>
<td>X</td>
<td>Approval Extension</td>
<td>277</td>
</tr>
<tr>
<td>XI</td>
<td>Prescription Code</td>
<td>278</td>
</tr>
<tr>
<td>XII</td>
<td>Beclomethasone - Assessment of Aerosol Weights</td>
<td>279</td>
</tr>
<tr>
<td>XIII</td>
<td>Pamphlets</td>
<td>280</td>
</tr>
<tr>
<td>XIV</td>
<td>Reading Tests</td>
<td>286</td>
</tr>
<tr>
<td>XV</td>
<td>Information Sheet for Pharmacists</td>
<td>289</td>
</tr>
<tr>
<td>XVI</td>
<td>Protocol for Pharmacists</td>
<td>290</td>
</tr>
<tr>
<td>XVII</td>
<td>Patient Information Sheet</td>
<td>291</td>
</tr>
<tr>
<td>XVIII</td>
<td>Patient Questionnaires</td>
<td>292</td>
</tr>
<tr>
<td>XIX</td>
<td>Medication Adherence Assessment (Morisky et al)</td>
<td>301</td>
</tr>
<tr>
<td>XX</td>
<td>Pharmacist Assessment of Involvement in the Project</td>
<td>302</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>ACEI</td>
<td>ACE-inhibitor</td>
<td></td>
</tr>
<tr>
<td>ADR</td>
<td>adverse drug reaction</td>
<td></td>
</tr>
<tr>
<td>BIDS</td>
<td>Bath Information and Data Service</td>
<td></td>
</tr>
<tr>
<td>BMA</td>
<td>British Medical Association</td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>congestive heart failure</td>
<td></td>
</tr>
<tr>
<td>COE</td>
<td>category of effectiveness</td>
<td></td>
</tr>
<tr>
<td>CPI</td>
<td>consumer product information</td>
<td></td>
</tr>
<tr>
<td>CMI</td>
<td>consumer medicine information</td>
<td></td>
</tr>
<tr>
<td>CCU</td>
<td>Critical Care Unit</td>
<td></td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration (USA)</td>
<td></td>
</tr>
<tr>
<td>GP</td>
<td>general practitioner</td>
<td></td>
</tr>
<tr>
<td>HBM</td>
<td>Health Belief Model</td>
<td></td>
</tr>
<tr>
<td>HV</td>
<td>home visit</td>
<td></td>
</tr>
<tr>
<td>IPA</td>
<td>Independent Practitioner Association</td>
<td></td>
</tr>
<tr>
<td>LOE</td>
<td>likelihood of effectiveness</td>
<td></td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
<td></td>
</tr>
<tr>
<td>MOS</td>
<td>Medical Outcomes Study</td>
<td></td>
</tr>
<tr>
<td>NSAID</td>
<td>non-steroidal anti-inflammatory drug</td>
<td></td>
</tr>
<tr>
<td>NHP</td>
<td>Nottingham Health Profile</td>
<td></td>
</tr>
<tr>
<td>NNT</td>
<td>number needed to be treated to obtain an effect</td>
<td></td>
</tr>
<tr>
<td>OBRA</td>
<td>Omnibus Budget Reconciliation Act</td>
<td></td>
</tr>
<tr>
<td>PHARMAC</td>
<td>Pharmaceutical Management Agency Ltd</td>
<td></td>
</tr>
<tr>
<td>pHx</td>
<td>past history</td>
<td></td>
</tr>
<tr>
<td>QoL</td>
<td>quality of life</td>
<td></td>
</tr>
<tr>
<td>RCT</td>
<td>randomised controlled trial</td>
<td></td>
</tr>
<tr>
<td>SF-36</td>
<td>Short-Form Questionnaire developed from Medical Outcomes Study</td>
<td></td>
</tr>
<tr>
<td>SPC</td>
<td>summary of product characteristics</td>
<td></td>
</tr>
<tr>
<td>USPDI</td>
<td>United States Pharmacopeia Drug Information Service</td>
<td></td>
</tr>
</tbody>
</table>